<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590444</url>
  </required_header>
  <id_info>
    <org_study_id>EK 10-147-0910</org_study_id>
    <nct_id>NCT03590444</nct_id>
  </id_info>
  <brief_title>Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser</brief_title>
  <official_title>Treatment of Diabetic Macular Edema (DME) With Intravitreal Anti-vascular Endothelial Growth Factor (Anti-VEGF) and Prompt Versus Deferred Focal Laser During Long-term Follow-up and Identification of Prognostic Retinal Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Hietzing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Hietzing</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal
      anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification
      of prognostic morphological characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term follow-up of patients with diabetic macular edema (DME) treated with intravitreal
      anti-vascular endothelial growth factor (anti-VEGF) combined focal laser and identification
      of prognostic morphological characteristics.

      Prospective clinical trial (50 treatment-naive eyes) with DME randomized 1:1 receiving
      intravitreal ranibizumab (0.5 mg/0.05 ml) and prompt grid laser compared to ranibizumab and
      deferred laser. Morphological characteristics potentially relevant for prognosis were
      assessed at baseline, month 6, month 9, year 1, 2, 3, 4 and 5 of follow-up.

      Grid laser and ranibizumab therapy is expected to be effective in DME management during
      long-term follow-up. Immediate combined therapy will likely signify a trend of functional
      superiority in an early disease phase. Intraretinal hyperreflective material in SD-OCT will
      likely negatively related to BCVA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2017</start_date>
  <completion_date type="Actual">June 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Functional alterations will be followed during treatment phase, essential for verification of treatment success. Units: Snellen equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional morphological characteristics in spectral Domain SD-OCT</measure>
    <time_frame>1 year</time_frame>
    <description>Intraretinal morphological features found in SD- OCT Imaging (i.e. intraretinal morphological changes senn on SD-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>1 year</time_frame>
    <description>Morphological alterations will be followed during treatment phase, essential for verification of treatment success. Units: Micrometer (retinal thickness)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetic Retinal Edema</condition>
  <arm_group>
    <arm_group_label>Prompt laser group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).
Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred laser group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).
Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5 MG/0.05 ML Intraocular Solution</intervention_name>
    <description>Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.
Ranibizumab 0.5 MG/0.05 ML Intraocular Solution</description>
    <arm_group_label>Deferred laser group</arm_group_label>
    <arm_group_label>Prompt laser group</arm_group_label>
    <other_name>Focal grid laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  DME that will be detected clinically and on FA as well as on SD-OCT [diffuse macular
             edema with central retinal thickness (CRT) ≥300µm involving the center of the macular
             area]

          -  Patients will be included into the present study following informed consent

          -  Best-corrected-visual-acuity (BCVA) between 0.06 (1.2logMAR) and 0.63 (0.20logMAR).

        Exclusion criteria:

          -  Eyes with other retinal diseases [i.e. age-related macular degeneration (AMD) and
             associated choroidal neovascularization (CNV), cystoid macular edema (CME) of other
             origin (e.g. uveitis, Irvine-Gass syndrome, retinal vein occlusion), or retinal
             dystrophies]
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Schütze, Ass.Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hietzing Hospital Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hietzing Hospital</name>
      <address>
        <city>VIenna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Hietzing</investigator_affiliation>
    <investigator_full_name>Christopher Schütze, Ass.Prof., MD, PhD</investigator_full_name>
    <investigator_title>Ass.Prof.MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilledema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

